Mitchell Berenson

Mitchell Berenson

Auto-generated profile, based on publicly available information

Mitchell Berenson

IV Ensure, Inc , Dallas, Texas

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2026 in Clinical Infectious Diseases
Verified
Journal Article
Open access
ESEmily A Siegrist
Emily A Siegrist
MBMitchell Berenson
Mitchell Berenson
JDJustin D Dvorak
Justin D Dvorak
JDJacob K Dozier
Jacob K Dozier
SWS Rae Wannier
S Rae Wannier
JSJoseph Sassine
Joseph Sassine
Background: Unplanned healthcare utilization events, including hospital readmissions and emergency room visits, are common in patients receiving outpatient parenteral antimicrobial therapy (OPAT). Little is known about patient adherence to therapy in this setting. This clinical trial evaluates the impact of a remote therapeutic monitoring (RTM) device with an integrated care platform on all-cause healthcare utilization in patients on OPAT. Methods: This prospective, open-label, nonrandomized study enrolled patients discharged on OPAT to receive the IV Ensure RTM device compared to contemporaneous controls. The primary outcome was all-cause healthcare utilization, including hospital readmission or emergency room visit, assessed at day 90 after discharge. Adherence to antimicrobial therapy was evaluated in the intervention group. Results: A total of 81 patients were enrolled in the intervention group, with 131 patients in the control group. Both groups had similar baseline and OPAT characteristics. On multivariate Cox regression analysis, the RTM intervention was associated with a 39% reduction in all-cause healthcare utilization by day 60 (adjusted hazard ratio, 0.61 [95% confidence interval, .38–.96]; P = .03]) and a 38% reduction by day 90 (0.62 [.40–.95]; P = .03). In the intervention group, the overall adherence reached a median of 94%, and 61.7% of patients maintained adherence of >90% throughout their OPAT course. Conclusions: An RTM device with an integrated care platform significantly reduced all-cause healthcare utilization events in patients on OPAT.